Long-acting Medication Use in COPD: Opportunities for Minimizing Medication Waste in the Hospital Setting

Chronic obstructive pulmonary disease (COPD) is the third most common cause of death in the United States1 and is responsible for approximately 700,000 hospitalizations each year.2 COPD-related costs in the United States exceed $50 billion per year and are expected to increase.3 The increasing costs associated with COPD management are a substantial burden on the health care system. To help manage this burden, current guidelines recommend the use of several long-acting inhaled medications for the treatment of COPD.4 In this white paper, learn about current guidelines for management of COPD and available dosage forms of long-acting inhaled medications, and recognize opportunities that may reduce medication waste through appropriate use of available COPD treatments. This supplement was developed by Pharmacy Times® with support from Sunovion Pharmaceuticals Inc. SUNOVION is a registered trademark of Sumitomo Dainippon Pharma Co., Ltd. Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ©2017 Sunovion Pharmaceuticals Inc. All rights reserved. 10/17 LEG-BRO021-17 To access this publication, Long-acting Medication Use in COPD: Opportunities for Minimizing Medication Waste in the Hospital Setting, please click here or on the button below. References Hoyert DL, Xu J; Centers for Disease Control and Prevention. Deaths: preliminary data for 2011. National Vital Statistics Reports. 2012;61(6):1-52. www.cdc.gov/nchs/data/nvsr/nvsr61/nvsr61_06.pdf. Accessed June 26, 2017. Krishnan JA, Gussin HA, Prieto-Centurion V, Sullivan JL, Zaidi F, Thomashow BM. Integrating COPD into patient-centered hospital readmissions reduction programs. Chronic Obstr Pulm Dis. 2015;2(1):70-80. Guarascio AJ, Ray SM, Finch CK, Self TH. The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinicoecon Outcomes Res. 2013;5:235-245. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2017:1-123.

Trending on Pharmacy Times

FDA Announces Recall 580,000 Bottles of Prazosin Over Potential Carcinogenic Impurity

Regular Melatonin Supplementation May Hide Hidden Heart Complications

CDC Adolescents, Children, & Adult Immunization Schedule: 2025 Update

Tick-Borne Encephalitis Among Travelers to Europe Highlights Need for Expanded Vaccination Efforts

How Rapid RSV Testing Shapes Clinical Decisions and Patient Outcomes